Cullinan Oncology LLC (CGEM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cullinan Oncology LLC (CGEM) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.05 Million) by net assets ($366.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cullinan Oncology LLC balance sheet independence to measure how much of total assets are equity-financed.
Cullinan Oncology LLC - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Cullinan Oncology LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CGEM cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Cullinan Oncology LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cullinan Oncology LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xvivo Perfusion AB
ST:XVIVO
|
0.030x |
|
GrocerIQ, Inc
NYSE:WPFHD
|
N/A |
|
Beijing Oriental Jicheng Co Ltd
SHE:002819
|
0.017x |
|
Domino's Pizza Enterprises Limited
F:HQX
|
0.082x |
|
Hna-Caissa Travel Group Co Ltd
SHE:000796
|
-0.094x |
|
Elevra Lithium Limited
AU:ELV
|
-0.051x |
|
Guangzhou Hengyun Enterprises Holding Ltd
SHE:000531
|
0.058x |
|
Shantou Wanshun Package Material
SHE:300057
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Cullinan Oncology LLC (2013–2025)
The table below shows the annual cash flow conversion efficiency of Cullinan Oncology LLC from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see CGEM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $408.73 Million | $-175.75 Million | -0.430x | -74.69% |
| 2024-12-31 | $590.33 Million | $-145.30 Million | -0.246x | +16.80% |
| 2023-12-31 | $453.89 Million | $-134.28 Million | -0.296x | -24.96% |
| 2022-12-31 | $535.03 Million | $-126.66 Million | -0.237x | -131.86% |
| 2021-12-31 | $425.37 Million | $-43.43 Million | -0.102x | +31.30% |
| 2020-12-31 | $200.31 Million | $-29.77 Million | -0.149x | -128.38% |
| 2019-12-31 | $-39.91 Million | $-20.90 Million | 0.524x | -20.20% |
| 2018-12-31 | $-20.65 Million | $-13.55 Million | 0.656x | +64.77% |
| 2016-12-31 | $-574.85K | $-228.91K | 0.398x | +1962.80% |
| 2015-12-31 | $-1.24 Million | $-24.03K | 0.019x | -76.10% |
| 2014-12-31 | $-1.14 Million | $-91.72K | 0.081x | -88.70% |
| 2013-12-31 | $-1.00 Million | $-718.41K | 0.715x | -- |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more